n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid has been researched along with Experimental Mammary Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruchertseifer, F; Lingappa, M; Morgenstern, A; Sgouros, G; Song, H; Thompson, S | 1 |
| Brechbiel, MW; Kelly, MP; Lee, FT; Scott, AM; Smyth, FE; Tahtis, K | 1 |
2 other study(ies) available for n-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-n,n',n',n'',n''-pentaacetic acid and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer.
Topics: Alpha Particles; Animals; Bismuth; Female; Immunoconjugates; Isothiocyanates; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Metastasis; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Rats; Receptor, ErbB-2 | 2010 |
Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Bismuth; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Immunoglobulin Fab Fragments; Isothiocyanates; Lewis Blood Group Antigens; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Survival Rate; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |